ID: ALA558235

Max Phase: Preclinical

Molecular Formula: C25H29ClN4O6S

Molecular Weight: 512.59

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(S(=O)(=O)Nc2ccc(C)c(CC(=O)NCc3ccc(C(=N)N)cc3)c2O)cc1OC.Cl

Standard InChI:  InChI=1S/C25H28N4O6S.ClH/c1-15-4-10-20(29-36(32,33)18-9-11-21(34-2)22(12-18)35-3)24(31)19(15)13-23(30)28-14-16-5-7-17(8-6-16)25(26)27;/h4-12,29,31H,13-14H2,1-3H3,(H3,26,27)(H,28,30);1H

Standard InChI Key:  ZRWDRDWMZSTISH-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 512.59

Molecular Weight (Monoisotopic): 512.1730

AlogP: 2.66

#Rotatable Bonds: 10

Polar Surface Area: 163.83

Molecular Species: BASE

HBA: 7

HBD: 5

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 7.23

CX Basic pKa: 11.42

CX LogP: 2.44

CX LogD: 2.23

Aromatic Rings: 3

Heavy Atoms: 36

QED Weighted: 0.16

Np Likeness Score: -0.98

References

1. Hanessian S, Therrien E, van Otterlo WA, Bayrakdarian M, Nilsson I, Fjellström O, Xue Y..  (2006)  Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.,  16  (4): [PMID:16290930] [10.1016/j.bmcl.2005.10.082]

Source

Source(1):

• Scientific Literature